Nature’s Miracle Mutually Agrees to Terminate Plan to Merge with Agrify Corp

Nature's Miracle Holding Inc. (NASDAQ:NMHI) ("Nature's Miracle" or the "Company"), a leader in vertical farming technology and infrastructure, announced today that both Nature's Miracle

Nature’s Miracle Holding Inc. (NASDAQ:NMHI) (“Nature’s Miracle” or the “Company”), a leader in vertical farming technology and infrastructure, announced today that both Nature’s Miracle and Agrify Corporation (NASDAQ:AGFY) (“Agrify”), have mutually agreed to terminate the previously announced plan to merge, originally announced on May 16, 2024. Given unfavorable market conditions, a decision was reached to terminate the planned merger.

In connection with the termination of its plan to acquire Agrify, the Company and Agrify have executed a termination agreement with respect to the merger agreement and have also executed a debt termination agreement with entities controlled by Agrify’s Chief Executive Officer with respect to the purchase of outstanding debt. Each of the termination agreements contained mutual releases.  Both the “Merger Agreement” and “Purchase of Notes” agreements have been cancelled with no termination or cancellation fees attached to either party. 

Total
0
Shares
Related Posts
Read More

SilverBow Resources Sends Letter To Shareholders Highlighting Path Forward For Value Creation; SilverBow Resources Provides Company Perspective On Kimmeridge’s Significant Overvaluation Of KTG And Massively Dilutive Proposal

SilverBow Resources Provides Company Perspective on Kimmeridge's Significant Overvaluation of KTG and Massively Dilutive ProposalBelieves Kimmeridge Efforts to Gain Control Through Proxy Fight Is Another Path to Forcing

SBOW

Read More

Reported Late Wednesday, G1 Therapeutics Provides Initial Results From Phase 2 Mechanism Of Action Trial In Early-Stage Triple Negative Breast Cancer Show That A Single Dose Of Trilaciclib Favorably Alters The Tumor Microenvironment

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided initial results from a 24 patient Phase 2 mechanism of action (MOA) trial showing favorable alterations in the tumor

GTHX